ABSTRACT
Description: LYMErix is a vaccine consisting of a recombinant outer surface lipoprotein A (L-OspA) from Borrelia burgdorferi sensu stricto. The 257-amino acid lipoprotein is produced in Escherichia coli and is provided as a suspension for intramuscular injection. Each single dose contains 30 µg active substance in 0.5 ml.
